Beactica Therapeutics Chooses BEA-28 for Preclinical Trials as a Novel TEAD Degrader #Sweden #Uppsala #Beactica #BEA-28 #TEAD_degrader

Beactica Therapeutics Chooses BEA-28 for Preclinical Trials as a Novel TEAD Degrader #Sweden #Uppsala #Beactica #BEA-28 #TEAD_degrader
Beactica Therapeutics Kicks Off IND-Enabling Studies for First-in-Class Glioblastoma Drug BEA-17 #Sweden #Glioblastoma #Uppsala #BEA-17 #Beactica
Beactica Therapeutics Advances Innovative Drug BEA-17 for Glioblastoma Treatment #Sweden #Glioblastoma #Uppsala #BEA-17 #Beactica